FDA DRUG APPROVAL PROCESS: A CHALLENGING TASK
The FDA is gatekeeper for access to new drugs. As such, it gets a lot of scrutiny time. Different peoples have different opinions. There are those who claim that the FDA is too lenient in its decision making process and that it unleashes unproven new drugs on an unsuspecting public that presumes any medicine approved is safe and efficacious. Others will assail the FDA as being far too conservative and say that the agency is unnecessarily delaying access to new life-saving drugs because of its bureaucracy.


The School of Chinese Medicine (SCM) of Hong Kong Baptist University (HKBU) is the first University Grants Committee (UGC) funded institution that provides higher education in Chinese medicine in Hong Kong. The School has all along been striving to promote the modernization and internationalization of Chinese medicine in teaching, research, clinical service and technology, with the aim to contribute to the development of Chinese medicine in Hong Kong. Through the unwavering efforts of all members of staff over the years, the School has already become the leading institution in Chinese medicine education in Hong Kong.
